vimarsana.com

Preliminary Results for the year ended 31 December 2022FDA CLEARANCE A MAJOR BREAKTHROUGH FOR PARSORTIX LIQUID BIOPSParsortix system substantially out-performs standard of care for ovarian cancer diagnosisProstate

Related Keywords

New Zealand ,China ,Zurich ,Züsz ,Switzerland ,Austria ,India ,Czech Republic ,Ukraine ,Pennsylvania ,United States ,France ,United Kingdom ,Canada ,Spain ,Russia ,Germany ,Guildford ,Surrey ,London ,City Of ,Toronto ,Ontario ,Plymouth Meeting ,Swiss ,Andrew Newland ,Milo Bonser ,Shaam Vora ,Toby Flaux ,Garth Selvey ,Ciaran Walsh ,Ian Griffiths ,Ciara Martin ,Juliet Thompson ,Simon Conway ,Parsortix Ctcs ,Thomas Bective ,Joe Eid ,Investor Centre ,Company United States ,Financial Conduct Authority ,Molecular Oncology Laboratory ,London Stock Exchange ,Centers For Medicare ,Interpretations International Financial Reporting Interpretation Committee ,Surrey Research Park ,Employee Share Ownership Trust ,Medicaid Services ,Swiss Federal Institute Of Technology ,Solaris Health ,Solaris Health Holdings ,Midlantic Urology ,Registrar Of Companies ,Group Financial ,Preliminary Results ,Crescendo Biologics ,Non Executive Directors ,Non Executive Chairman ,Joint Broker ,Frequently Used Terms ,Abuse Regulation ,Swiss Federal Institute ,Middle East ,Lantic Urology ,Financial Statements ,Companies Act ,Consolidated Financial Statements ,Annual General ,United Kingdom Adopted ,Annual General Meeting ,Holiday Inn Guildford ,Egerton Road ,London Stock ,Primary Information Provider ,Angle ,Nnounces ,Results ,Ear ,Nded ,December ,022 ,

© 2024 Vimarsana

vimarsana.com © 2020. All Rights Reserved.